John J Mariani1,2, Amy Mahony1, Muhammad N Iqbal1, Sean X Luo1,2, Nasir H Naqvi1,2, Frances R Levin1,2. 1. Division on Substance Use Disorders, New York State Psychiatric Institute, New York, New York. 2. Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
Abstract
BACKGROUND AND OBJECTIVES: Highly potent synthetic opioids (HPSO) are increasingly responsible for opioid overdose deaths in the United States. METHODS: In an open-label, uncontrolled trial to test the feasibility of extended-release buprenorphine (BXR) injection treatment of heroin-using individuals with opioid use disorder testing positive for HPSO, participants were enrolled and began an induction with sublingual BXR (n = 5). During the induction, ancillary medications (clonidine, clonazepam, zolpidem, and prochlorperazine) were provided for breakthrough opioid withdrawal symptoms. RESULTS: Two participants received the BXR injection on the second day of the induction and three participants on the third day. DISCUSSION AND CONCLUSION: All five participants were retained at least 1-month postinduction. SCIENTIFIC SIGNIFICANCE: It may be feasible to provide BXR treatment to HPSO-positive heroin users rapidly to achieve clinical stabilization. (Am J Addict 2020;00:00-00).
BACKGROUND AND OBJECTIVES: Highly potent synthetic opioids (HPSO) are increasingly responsible for opioid overdose deaths in the United States. METHODS: In an open-label, uncontrolled trial to test the feasibility of extended-release buprenorphine (BXR) injection treatment of heroin-using individuals with opioid use disorder testing positive for HPSO, participants were enrolled and began an induction with sublingual BXR (n = 5). During the induction, ancillary medications (clonidine, clonazepam, zolpidem, and prochlorperazine) were provided for breakthrough opioid withdrawal symptoms. RESULTS: Two participants received the BXR injection on the second day of the induction and three participants on the third day. DISCUSSION AND CONCLUSION: All five participants were retained at least 1-month postinduction. SCIENTIFIC SIGNIFICANCE: It may be feasible to provide BXR treatment to HPSO-positive heroin users rapidly to achieve clinical stabilization. (Am J Addict 2020;00:00-00).
Authors: Azmi F Nasser; Mark K Greenwald; Bradley Vince; Paul J Fudala; Philip Twumasi-Ankrah; Yongzhen Liu; J P Jones; Christian Heidbreder Journal: J Clin Psychopharmacol Date: 2016-02 Impact factor: 3.153
Authors: Jake R Morgan; Alexander Y Walley; Sean M Murphy; Avik Chatterjee; Scott E Hadland; Joshua Barocas; Benjamin P Linas; Sabrina A Assoumou Journal: Drug Alcohol Depend Date: 2021-05-21 Impact factor: 4.852
Authors: Nikhil Seval; Cynthia A Frank; Alain H Litwin; Prerana Roth; Meredith A Schade; Martina Pavlicova; Frances R Levin; Kathleen T Brady; Edward V Nunes; Sandra A Springer Journal: Contemp Clin Trials Date: 2021-04-07 Impact factor: 2.261
Authors: John J Mariani; Amy L Mahony; Samuel C Podell; Daniel J Brooks; Christina Brezing; Sean X Luo; Nasir H Naqvi; Frances R Levin Journal: Am J Addict Date: 2021-07-05